[{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Haystack Oncology","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Haystack Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Haystack Oncology \/ Lisata Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Haystack Oncology \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Amgen Inc"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","sponsor":"ClinAssess","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH \/ ClinAssess","highestDevelopmentStatusID":"8","companyTruncated":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH \/ ClinAssess"},{"orgOrder":0,"company":"Ludwig Maximilian University of Munich","sponsor":"Amgen Inc | ClinAssess","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Ludwig Maximilian University of Munich","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ludwig Maximilian University of Munich \/ Amgen Inc | ClinAssess","highestDevelopmentStatusID":"8","companyTruncated":"Ludwig Maximilian University of Munich \/ Amgen Inc | ClinAssess"},{"orgOrder":0,"company":"AIO-Studien-gGmbH","sponsor":"Amgen Inc | Assign Data Management and Biostatistics | Assign Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"AIO-Studien-gGmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AIO-Studien-gGmbH \/ Amgen Inc | Assign Data Management and Biostatistics | Assign Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"AIO-Studien-gGmbH \/ Amgen Inc | Assign Data Management and Biostatistics | Assign Clinical Research"},{"orgOrder":0,"company":"Hellenic Cooperative Oncology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Hellenic Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hellenic Cooperative Oncology Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hellenic Cooperative Oncology Group \/ Undisclosed"},{"orgOrder":0,"company":"Hellenic Cooperative Oncology Group","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Hellenic Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hellenic Cooperative Oncology Group \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Hellenic Cooperative Oncology Group \/ Amgen Inc"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"Amgen Inc | AstraZeneca | Bayer AG | Bristol Myers Squibb | Novartis Pharmaceuticals Corporation | F. Hoffmann-La Roche | Merck & Co | Boehringer Ingelheim GmbH | Ipsen | Eisai Inc | Pfizer Inc | Clovis Oncology | Eli Lilly | Johnson & Johnson Innovative ","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Netherlands Cancer Institute \/ Amgen Inc | AstraZeneca | Bayer AG | Bristol Myers Squibb | Novartis Pharmaceuticals Corporation | F. Hoffmann-La Roche | Merck & Co | Boehringer Ingelheim GmbH | Ipsen | Eisai Inc | Pfizer Inc | Clovis Oncology | Eli Lilly | Johnson & Johnson Innovative ","highestDevelopmentStatusID":"8","companyTruncated":"The Netherlands Cancer Institute \/ Amgen Inc | AstraZeneca | Bayer AG | Bristol Myers Squibb | Novartis Pharmaceuticals Corporation | F. Hoffmann-La Roche | Merck & Co | Boehringer Ingelheim GmbH | Ipsen | Eisai Inc | Pfizer Inc | Clovis Oncology | Eli Lilly | Johnson & Johnson Innovative "},{"orgOrder":0,"company":"Grupo Espanol Multidisciplinario del Cancer Digestivo","sponsor":"Amgen Inc | TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Grupo Espanol Multidisciplinario del Cancer Digestivo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grupo Espanol Multidisciplinario del Cancer Digestivo \/ Amgen Inc | TFS Trial Form Support","highestDevelopmentStatusID":"8","companyTruncated":"Grupo Espanol Multidisciplinario del Cancer Digestivo \/ Amgen Inc | TFS Trial Form Support"},{"orgOrder":0,"company":"Grupo Espanol Multidisciplinario del Cancer Digestivo","sponsor":"Amgen Inc | Pivotal S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Grupo Espanol Multidisciplinario del Cancer Digestivo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grupo Espanol Multidisciplinario del Cancer Digestivo \/ Amgen Inc | Pivotal S.L.","highestDevelopmentStatusID":"8","companyTruncated":"Grupo Espanol Multidisciplinario del Cancer Digestivo \/ Amgen Inc | Pivotal S.L."},{"orgOrder":0,"company":"Grupo Espanol Multidisciplinario del Cancer Digestivo","sponsor":"Amgen Inc | Pivotal S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Grupo Espanol Multidisciplinario del Cancer Digestivo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grupo Espanol Multidisciplinario del Cancer Digestivo \/ Amgen Inc | Pivotal S.L.","highestDevelopmentStatusID":"8","companyTruncated":"Grupo Espanol Multidisciplinario del Cancer Digestivo \/ Amgen Inc | Pivotal S.L."},{"orgOrder":0,"company":"Grupo Espanol Multidisciplinario del Cancer Digestivo","sponsor":"Amgen Inc | Trial Form Support S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Grupo Espanol Multidisciplinario del Cancer Digestivo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grupo Espanol Multidisciplinario del Cancer Digestivo \/ Amgen Inc | Trial Form Support S.L.","highestDevelopmentStatusID":"8","companyTruncated":"Grupo Espanol Multidisciplinario del Cancer Digestivo \/ Amgen Inc | Trial Form Support S.L."},{"orgOrder":0,"company":"Spanish Cooperative Group for Digestive Tumours","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Spanish Cooperative Group for Digestive Tumours","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Cooperative Group for Digestive Tumours \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Spanish Cooperative Group for Digestive Tumours \/ Amgen Inc"},{"orgOrder":0,"company":"Spanish Cooperative Group for Digestive Tumours","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Spanish Cooperative Group for Digestive Tumours","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Cooperative Group for Digestive Tumours \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spanish Cooperative Group for Digestive Tumours \/ Undisclosed"},{"orgOrder":0,"company":"Grupo Espanol Multidisciplinario del Cancer Digestivo","sponsor":"Pivotal S.L. | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Grupo Espanol Multidisciplinario del Cancer Digestivo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espanol Multidisciplinario del Cancer Digestivo \/ Pivotal S.L. | Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Grupo Espanol Multidisciplinario del Cancer Digestivo \/ Pivotal S.L. | Amgen Inc"},{"orgOrder":0,"company":"Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials \/ Amgen Inc"},{"orgOrder":0,"company":"Grupo Gallego de Investigaciones Oncologicas","sponsor":"Amgen Inc | Trial Form Support S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Grupo Gallego de Investigaciones Oncologicas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Gallego de Investigaciones Oncologicas \/ Amgen Inc | Trial Form Support S.L.","highestDevelopmentStatusID":"8","companyTruncated":"Grupo Gallego de Investigaciones Oncologicas \/ Amgen Inc | Trial Form Support S.L."},{"orgOrder":0,"company":"The Queen Elizabeth Hospital","sponsor":"Amgen Inc | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Queen Elizabeth Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Queen Elizabeth Hospital \/ Amgen Inc | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"The Queen Elizabeth Hospital \/ Amgen Inc | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"WiSP Wissenschaftlicher Service Pharma GmbH","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"WiSP Wissenschaftlicher Service Pharma GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WiSP Wissenschaftlicher Service Pharma GmbH \/ Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","highestDevelopmentStatusID":"8","companyTruncated":"WiSP Wissenschaftlicher Service Pharma GmbH \/ Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH"},{"orgOrder":0,"company":"WiSP Wissenschaftlicher Service Pharma GmbH","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"WiSP Wissenschaftlicher Service Pharma GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WiSP Wissenschaftlicher Service Pharma GmbH \/ Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","highestDevelopmentStatusID":"8","companyTruncated":"WiSP Wissenschaftlicher Service Pharma GmbH \/ Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH"},{"orgOrder":0,"company":"WiSP Wissenschaftlicher Service Pharma GmbH","sponsor":"ClinAssess","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"WiSP Wissenschaftlicher Service Pharma GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WiSP Wissenschaftlicher Service Pharma GmbH \/ ClinAssess","highestDevelopmentStatusID":"8","companyTruncated":"WiSP Wissenschaftlicher Service Pharma GmbH \/ ClinAssess"},{"orgOrder":0,"company":"University of Southern California","sponsor":"National Cancer Institute | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"University of Southern California","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern California \/ National Cancer Institute | Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"University of Southern California \/ National Cancer Institute | Amgen Inc"},{"orgOrder":0,"company":"Accelerated Community Oncology Research Network","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Accelerated Community Oncology Research Network","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accelerated Community Oncology Research Network \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Accelerated Community Oncology Research Network \/ Amgen Inc"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Georgetown University \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Boston Medical Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Boston Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boston Medical Center \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Boston Medical Center \/ Amgen Inc"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Rochester \/ Amgen Inc"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ Amgen Inc"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"Amgen Inc | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ Amgen Inc | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ Amgen Inc | Bristol Myers Squibb"},{"orgOrder":0,"company":"Women and Infants Hospital of Rhode Island","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Women and Infants Hospital of Rhode Island","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Women and Infants Hospital of Rhode Island \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Women and Infants Hospital of Rhode Island \/ Amgen Inc"},{"orgOrder":0,"company":"SCRI Development Innovations, LLC","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"SCRI Development Innovations, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SCRI Development Innovations, LLC \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"SCRI Development Innovations, LLC \/ Amgen Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Amgen Inc"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Wisconsin, Madison \/ Amgen Inc"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Panitumumab","moa":"||Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Genentech"},{"orgOrder":0,"company":"TTCC","sponsor":"Amgen Inc | Trial Form Support S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"TTCC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TTCC \/ Amgen Inc | Trial Form Support S.L.","highestDevelopmentStatusID":"8","companyTruncated":"TTCC \/ Amgen Inc | Trial Form Support S.L."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amsterdam UMC, VUmc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amsterdam UMC, VUmc","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Amsterdam UMC, VUmc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"John Hays","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Amgen Inc \/ John Hays","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ John Hays"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Neal Ready","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Neal Ready","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Neal Ready"},{"orgOrder":0,"company":"Exelixis","sponsor":"John Strickler","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exelixis \/ John Strickler","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ John Strickler"}]
Find Clinical Drug Pipeline Developments & Deals for Panitumumab
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
